Jin Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jin Han has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Santosh Lumdas Saraf
Division of Hematology & Oncology, Department of Medicine University of Illinois at Chicago Chicago Illinois USA
26 shared publications Victor R. Gordeuk
Division of Hematology & Oncology, Department of Medicine University of Illinois at Chicago Chicago Illinois USA
23 shared publicationsRobert E. Molokie
Sickle Cell Center, Division of Hematology & Oncology University of Illinois Chicago Chicago Illinois USA
19 shared publicationsMichel Gowhari
17 shared publications- Victor R. Gordeuk
Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
16 shared publications Santosh L. Saraf
13 shared publications
Latest Publications
- Open Access
- 3 December 2025
- Published by Wiley in American Journal of Hematology
- Vol. 101 (2) , 304-310
Albuminuria Predicts a Rapid Decline in Kidney Function in 2 International, Longitudinal Cohorts of Adults With Sickle Cell Anemia
Chronic kidney disease (CKD) is common and a major contributor to increased morbidity and early mortality in people with sickle cell anemia (SCA). Urine albumin‐to‐creatinine ratio (uACR) is recommended to identify patients with SCA‐related CKD but its utility in predicting long‐term kidney dysfunction remains unclear in this patient population. In two independent, longitudinal cohorts of patients with hemoglobin SS or Sβ 0 ‐thalassemia (USA: n = 268, median follow‐up 6 years; France: n = 310, median follow‐up 8.2 years) we investigated the utility of uACR, as well as other clinical and modifiable risk factors, for predicting a decline in kidney function as determined by the rate of estimated glomerular filtration rate (eGFR) decline. Using linear mixed‐effects models, a higher baseline uACR independently predicted a faster rate of eGFR decline as well as a more rapid annual eGFR decline, defined as ≥ 3 mL/min/1.73m 2 ( p ≤ 0.009). Furthermore, baseline uACR of ≥ 100 mg/g creatinine was independently associated with the rate of eGFR decline and rapid annual eGFR decline in both cohorts. Tobacco smoking was also associated with a faster rate of eGFR decline and was congruous between the two cohorts. In conclusion, we demonstrate that uACR is an important clinical tool that predicts a more rapid decline in kidney function and should be routinely monitored in people with SCA. Our data also support preventative care to reduce tobacco smoking for mitigating the risk of CKD progression in this high‐risk population.
- 3 December 2025
- Published by Wiley in American Journal of Hematology
- Vol. 101 (2) , 304-310
Open AccessAlbuminuria Predicts a Rapid Decline in Kidney Function in 2 International, Longitudinal Cohorts of Adults With Sickle Cell Anemia
Chronic kidney disease (CKD) is common and a major contributor to increased morbidity and early mortality in people with sickle cell anemia (SCA). Urine albumin‐to‐creatinine ratio (uACR) is recommended to identify patients with SCA‐related CKD but its utility in predicting long‐term kidney dysfunction remains unclear in this patient population. In two independent, longitudinal cohorts of patients with hemoglobin SS or Sβ 0 ‐thalassemia (USA: n = 268, median follow‐up 6 years; France: n = 310, median follow‐up 8.2 years) we investigated the utility of uACR, as well as other clinical and modifiable risk factors, for predicting a decline in kidney function as determined by the rate of estimated glomerular filtration rate (eGFR) decline. Using linear mixed‐effects models, a higher baseline uACR independently predicted a faster rate of eGFR decline as well as a more rapid annual eGFR decline, defined as ≥ 3 mL/min/1.73m 2 ( p ≤ 0.009). Furthermore, baseline uACR of ≥ 100 mg/g creatinine was independently associated with the rate of eGFR decline and rapid annual eGFR decline in both cohorts. Tobacco smoking was also associated with a faster rate of eGFR decline and was congruous between the two cohorts. In conclusion, we demonstrate that uACR is an important clinical tool that predicts a more rapid decline in kidney function and should be routinely monitored in people with SCA. Our data also support preventative care to reduce tobacco smoking for mitigating the risk of CKD progression in this high‐risk population.
- 17 February 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (5) , 913-916
Steady‐State Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity Predicts Low Platelet Count at Hospitalization for Sickle Cell Disease Vaso‐Occlusive Episodes
- 17 February 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (5) , 913-916
Steady‐State Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity Predicts Low Platelet Count at Hospitalization for Sickle Cell Disease Vaso‐Occlusive Episodes
- 21 May 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 716-718
Alkaline phosphatase as a marker for painful vaso‐occlusive events and other acute complications in sickle cell disease
- 21 May 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 716-718
Alkaline phosphatase as a marker for painful vaso‐occlusive events and other acute complications in sickle cell disease
- 2 May 2024
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (7) , 293-298
Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention
Background: Previous differences in guideline recommendation strength for CYP2C19 intermediate metabolizers may have limited genotype (PGx)-optimal post-percutaneous coronary intervention antiplatelet prescribing. Results: In this single-center retrospective observational cohort study of CYP2C19 intermediate metabolizers, patients prescribed PGx-optimal therapy were younger and less likely on anticoagulation (2 vs 12%; p = 0.006). More patients prescribed PGx-optimal therapy possessed commercial insurance (36 vs 7%; p < 0.001), which was a predictor for PGx-optimal selection (OR: 6.464; 95% CI: 2.386-17.516; p < 0.001). Conclusion: Anticoagulation use was significantly associated with clopidogrel use (OR: 0.138; 95% CI: 0.026-0.730; p = 0.020). No statistical difference in composite major adverse cardiovascular events (5 vs 14%; p = 0.173) or bleeding (8 vs 6%; Not significant) was observed between PGx-optimal and PGx-suboptimal therapy.
- 2 May 2024
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 25 (7) , 293-298
Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention
Background: Previous differences in guideline recommendation strength for CYP2C19 intermediate metabolizers may have limited genotype (PGx)-optimal post-percutaneous coronary intervention antiplatelet prescribing. Results: In this single-center retrospective observational cohort study of CYP2C19 intermediate metabolizers, patients prescribed PGx-optimal therapy were younger and less likely on anticoagulation (2 vs 12%; p = 0.006). More patients prescribed PGx-optimal therapy possessed commercial insurance (36 vs 7%; p < 0.001), which was a predictor for PGx-optimal selection (OR: 6.464; 95% CI: 2.386-17.516; p < 0.001). Conclusion: Anticoagulation use was significantly associated with clopidogrel use (OR: 0.138; 95% CI: 0.026-0.730; p = 0.020). No statistical difference in composite major adverse cardiovascular events (5 vs 14%; p = 0.173) or bleeding (8 vs 6%; Not significant) was observed between PGx-optimal and PGx-suboptimal therapy.
- 24 April 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (8) , 1610-1612
GLP‐1 agonists and SGLT‐2 inhibitors in adults with sickle cell disease
- 24 April 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (8) , 1610-1612
GLP‐1 agonists and SGLT‐2 inhibitors in adults with sickle cell disease
- Open Access
- 22 June 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (5) , 916-918
Vaccination in sickle cell disease: Immunocompromised or immunocompetent?
Sickle cell disease (SCD) is an immunocompromised condition and patients with SCD may have a reduced immune response to certain vaccinations. The report by Nakahara et al. demonstrated that SCD patients exhibited elevated and more sustained IgG production following COVID-19 vaccination, when compared to healthy controls. This suggests that the immune response to vaccinations may vary among different types of vaccines in individuals with SCD.
- 22 June 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (5) , 916-918
Open AccessVaccination in sickle cell disease: Immunocompromised or immunocompetent?
Sickle cell disease (SCD) is an immunocompromised condition and patients with SCD may have a reduced immune response to certain vaccinations. The report by Nakahara et al. demonstrated that SCD patients exhibited elevated and more sustained IgG production following COVID-19 vaccination, when compared to healthy controls. This suggests that the immune response to vaccinations may vary among different types of vaccines in individuals with SCD.
- 8 May 2023
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 5 (7) , 101003
Use of activity restriction in women with preterm labor: do not take it for granted
- 8 May 2023
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 5 (7) , 101003
Use of activity restriction in women with preterm labor: do not take it for granted
- 1 April 2023
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 24 (6) , 303-314
Pharmacist-guided pharmacogenetic service lowered warfarin-related hospitalizations
Background: The authors aimed to assess outcomes with a pharmacogenetic (PGx)-informed, pharmacist-guided, personalized consult service for warfarin dosing. Methods: This retrospective cohort study...
- 1 April 2023
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 24 (6) , 303-314
Pharmacist-guided pharmacogenetic service lowered warfarin-related hospitalizations
Background: The authors aimed to assess outcomes with a pharmacogenetic (PGx)-informed, pharmacist-guided, personalized consult service for warfarin dosing. Methods: This retrospective cohort study...
- 4 September 2022
- Published by Wiley in British Journal of Haematology
- Vol. 199 (4) , E21-E24
COVID‐19 vaccination status and disease burden in patients with sickle cell disease
- 4 September 2022
- Published by Wiley in British Journal of Haematology
- Vol. 199 (4) , E21-E24
COVID‐19 vaccination status and disease burden in patients with sickle cell disease